FEMSelect Expands Pelvic Health Platform
FEMSelect, a pioneering medical technology company led by women, is revolutionizing women's health with its latest strategic distribution agreement with ARMS Medical. This collaboration is aimed at enhancing the innovative spirit of FEMSelect while providing valuable biologic solutions to the field of pelvic health.
Partnership Enhances Offerings for Surgeons
The partnership will allow FEMSelect to distribute ARMS Medical's advanced portfolio, particularly featuring VNEW® precut decellularized dermal allografts and DermaPure®. This integration will complement FEMSelect's existing EnPlace® system, further enriching the surgical options available for pelvic organ prolapse repair.
Strengthening Surgeon Engagement
With over 10,000 patients treated and more than 200 surgeons engaged, ARMS Medical has established a solid foundation in the urogynecology and pelvic reconstruction market. By incorporating ARMS Medical's biologic implants, FEMSelect can provide enhanced options for surgeons, promoting biologic solutions to meet the diverse needs of their patients.
Vision for Women's Health
Sasha Schrode, the Chief Executive Officer of FEMSelect, emphasized their commitment to developing a comprehensive portfolio that serves surgeons in critical areas of pelvic health. The addition of VNEW® and ARMS Medical's biologic offerings aligns with FEMSelect’s vision, reinforcing the innovative capabilities of the EnPlace® system.
Focused Growth Initiatives
This new partnership is part of a larger initiative as FEMSelect seeks to accelerate its growth trajectory within women's health. Recently, FEMSelect launched Elitone, a non-surgical treatment for incontinence, and is focusing on expanding its international presence. The adoption of these strategies, alongside a corporate reorganization, positions the company to scale successfully.
Commitment to Excellence
Robert Greer, CEO of ARMS Medical, shared insights about the strategic fit between the two organizations, stating that both companies aim to provide surgeons with high-quality biologic solutions that guide responsible, informed surgical practices. The collaboration is seen as beneficial to both the companies and the healthcare professionals involved.
About FEMSelect
FEMSelect leads the way in advancing treatment for pelvic floor disorders, spearheaded by their innovative EnPlace® technology, which provides a minimally invasive and mesh-free approach to pelvic organ prolapse. The company is dedicated to positioning itself as a leading force in women's pelvic health through strategic partnerships and portfolio enhancements.
About ARMS Medical
As a Service-Disabled Veteran-Owned Small Business, ARMS Medical specializes in biologic grafts and surgical implements specifically designed for pelvic floor reconstruction. Their collaboration with surgeons across the nation reflects their commitment to delivering anatomically informed solutions in pelvic surgery.
Frequently Asked Questions
What is FEMSelect's latest partnership about?
FEMSelect has formed a strategic distribution agreement with ARMS Medical to enhance its pelvic health offerings.
How will this partnership benefit surgeons?
Surgeons will gain access to additional biologic solutions which will complement FEMSelect's existing technologies.
What products are involved in the partnership?
The collaboration includes ARMS Medical's VNEW® allografts and DermaPure® implants.
What is EnPlace®?
EnPlace® is FEMSelect's innovative system for pelvic organ prolapse repair that is minimally invasive and mesh-free.
What is the mission of FEMSelect?
FEMSelect aims to enhance women's health care through innovative technologies and strategic growth initiatives.
